Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

SELL
$34.66 - $54.07 $7.12 Million - $11.1 Million
-205,400 Reduced 48.8%
215,477 $10.8 Million
Q1 2023

May 12, 2023

SELL
$36.27 - $47.2 $3.67 Million - $4.77 Million
-101,100 Reduced 19.37%
420,877 $15.8 Million
Q4 2022

Feb 13, 2023

BUY
$20.58 - $47.95 $8.82 Million - $20.6 Million
428,777 Added 460.06%
521,977 $25 Million
Q3 2022

Nov 14, 2022

BUY
$21.69 - $28.53 $446,814 - $587,718
20,600 Added 28.37%
93,200 $2.24 Million
Q2 2022

Aug 12, 2022

BUY
$17.68 - $26.58 $562,224 - $845,244
31,800 Added 77.94%
72,600 $1.58 Million
Q1 2022

May 13, 2022

BUY
$17.46 - $26.36 $485,388 - $732,808
27,800 Added 213.85%
40,800 $985,000
Q4 2021

Feb 11, 2022

BUY
$19.32 - $26.45 $251,160 - $343,850
13,000 New
13,000 $309,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $6.26B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.